Skip to Content

Halaven Side Effects

Generic Name: eribulin

Note: This page contains information about the side effects of eribulin. Some of the dosage forms included on this document may not apply to the brand name Halaven.

In Summary

Common side effects of Halaven include: urinary tract infection, severe neutropenia, alopecia, anemia, arthralgia, asthenia, back pain, cough, fatigue, headache, myalgia, neutropenia, ostealgia, paresthesia, peripheral neuropathy, peripheral sensory neuropathy, polyneuropathy, weight loss, neuropathy, and anorexia. Other side effects include: febrile neutropenia, and peripheral motor neuropathy. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to eribulin: intravenous solution

In addition to its needed effects, some unwanted effects may be caused by eribulin (the active ingredient contained in Halaven). In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking eribulin, check with your doctor or nurse immediately:

More common:
  • Black, tarry stools
  • bladder pain
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody or cloudy urine
  • body aches or pain
  • burning, numbness, tingling, or painful sensations
  • chills
  • convulsions
  • cough
  • decreased urine
  • decreased weight
  • difficult or labored breathing
  • difficult, burning, or painful urination
  • dry mouth
  • ear congestion
  • fever
  • frequent urge to urinate
  • headache
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • loss of voice
  • lower back or side pain
  • mood changes
  • muscle pain or cramps
  • nasal congestion
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • pale skin
  • rapid weight gain
  • runny nose
  • sneezing
  • sore throat
  • tightness in the chest
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • weakness in the arms, hands, legs, or feet
Incidence not known:
  • Fainting
  • irregular heartbeat, recurrent

Minor Side Effects

Some of the side effects that can occur with eribulin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common:
  • Acid or sour stomach
  • back pain
  • belching
  • bone pain
  • change in taste
  • cracked lips
  • depression
  • diarrhea
  • difficulty having a bowel movement (stool)
  • difficulty with moving
  • difficulty with swallowing
  • dizziness
  • hair loss or thinning of the hair
  • heartburn
  • indigestion
  • lack or loss of strength
  • loss of taste
  • muscle spasm or weakness
  • muscle stiffness
  • pain in the arms or legs
  • pain in the joints
  • rash
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • stomach discomfort, upset, or pain
  • swelling or inflammation of the mouth
  • trouble sleeping
  • watering of the eyes
  • weight loss

For Healthcare Professionals

Applies to eribulin: intravenous solution


Very common (10% or more): Neutropenia (up to 82%), anemia (up to 58%)
Very common (10% or more): Urinary tract infection (up to 10%)
Uncommon (0.1% to 1%): Dysuria, hematuria, proteinuria, hematuria, leukopenia, lymphopenia[Ref]

In one study, grade 3 neutropenia occurred in 28% of patients, 29% experience grade 4 neutropenia, and 5% of patients experienced febrile neutropenia. Dose reductions due to neutropenia occurred in 12% of patients and discontinuation was required in less than 1% of patients. Grade 3 or greater thrombocytopenia was reported in 1% of patients. Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor was used in 19% of patients treated with this drug.[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (up to 35%)
Common (1% to 10%): Dysgeusia, dizziness, hypoesthesia, lethargy, neurotoxicity, polyneuropathy, peripheral sensory neuropathy, paresthesia[Ref]


Very common (10% or more): Nausea (up to 35%), constipation (up to 25%), diarrhea (up to 18%), vomiting (up to 18%)
Common (1% to 10%): Abdominal pain, stomatitis, dry mouth, dyspepsia, gastroesophageal reflux disease, mouth ulceration, mucosal inflammation, abdominal distension
Postmarketing reports: Pancreatitis[Ref]


Common (1% to 10%): QT prolongation, tachycardia, peripheral edema[Ref]


Very common (10% or more): Alopecia (up to 45%)
Common (1% to 10%): Rash, pruritus, nail disorder, night sweats, palmar plantar erythrodysesthesia, dry skin, erythema, hyperhidrosis[Ref]


Very common (10% or more): Urinary tract infection (up to 10%)
Uncommon (0.1% to 1%): Dysuria, hematuria, proteinuria



Common (1% to 10%): Alanine aminotransferase increased, aspartate aminotransferase increased, gamma glutamyl transferase increased, hyperbilirubinemia[Ref]


Very common (10% or more): Weight decreased (up to 21%), anorexia (up to 20%)
Common (1% to 10%): Hypokalemia[Ref]


Very common (10% or more): Arthralgia/Myalgia (up to 22%), back pain (up to 16%), bone pain (up to 12%), pain in extremity (up to 11%)
Common (1% to 10%): Muscle spasms, musculoskeletal pain, musculoskeletal chest pain[Ref]


Common (1% to 10%): Lacrimation increased, conjunctivitis[Ref]


Very common (10% or more): Asthenia/Fatigue (up to 54%), pyrexia (up to 21%)
Common (1% to 10%): Disseminated intravascular coagulation, oral herpes, mucosal inflammation, hot flushes, pain, chills, peripheral neuropathy, headache
Frequency not reported: Tinnitus[Ref]


Very common (10% or more): Headache
Common (1% to 10%): Insomnia, depression[Ref]


Very common (10% or more): Dyspnea (up to 16%), cough (up to 14%)
Rare (less than 0.1%): Upper respiratory tract infection, nasopharyngitis, rhinitis
Frequency not reported: Oropharyngeal pain, epistaxis, rhinorrhea[Ref]


Very common (10% or more):
Common (1% to 10%): Oral candidiasis, influenza-like illness, mucosal inflammation
Postmarketing reports: Pneumonia, sepsis/neutropenic sepsis[Ref]


1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL:" ([2006]):

3. "Product Information. Halaven (eribulin)." Eisai Inc, Teaneck, NJ.

Not all side effects for Halaven may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.